The P.I. is investigating a novel method for the functional inactivation of estrogen receptors (ERs) in estrogen- dependent human breast cancer cells based on the use of potent dominant negative (DN) ER mutants. The P.I. has generated several potent DN-ERs and shown that they inhibit estrogen-stimulated gene expression and proliferation of breast cancer cells. The present proposal focuses on two critical advances made during this work: 1 the identification by 2-hybrid interaction cloning of a novel corepressor protein, denoted REA for repressor of estrogen action. REA selectively enhance the potency of DN-ERs, while having very little effect on wild type ER and no effect on other nuclear receptors. 2) The development of a system for generating targeted DN-ERs which bind with high affinity and selectivity to specific hormone response elements.
The Specific Aims are: 1) To analyze the molecular mechanisms by which the corepressor REA is recruited by DN-ERs and potentiates their activity. Physica and functional mapping of DN-ER/REA interaction will be carried out using GST pull-down methods, mammalian 2-hybrid transactivation assays and mutational analyses. Using antibodies to REA, and antisense methodology, intracellular RE will be neutralized/eliminated and the functional importance of the DN-ER/REA interaction will be defined in intact cells. The P.I. will identify additional REA interaction partners which may potentiate corepressor activity, and characterize the effect of REA on ER cellular distribution. 2) To search for other dominant negative corepressors, the P.I. will use 2-hybrid interaction cloning with the two most potent DN-ERs. 3) To optimize receptor-corepressor interaction, 2-hybrid screening with REA will be used to screen ER mutant libraries for mutants exhibiting enhanced corepressor binding. 4) To assess the roles of the c-myc, TGFa and cathepsin D genes in the proliferation and invasiveness of ER positive breast cancer cells, the modified P22 challenge phage system will be used to create DN-ERs that bind selectively and with high affinity to the different non-consensus EREs found in each of these genes. The P.I. will introduce the gene- selective DN-ERs into cells using her efficient adenovirus system, determine their effects on gene expression, and examine their importance in ER regulated breast cancer cell proliferation and invasiveness.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA060514-10
Application #
6512967
Study Section
Reproductive Endocrinology Study Section (REN)
Program Officer
Sathyamoorthy, Neeraja
Project Start
1993-07-15
Project End
2004-04-30
Budget Start
2002-05-01
Budget End
2004-04-30
Support Year
10
Fiscal Year
2002
Total Cost
$319,466
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Physiology
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Martini, Paolo G V; Katzenellenbogen, Benita S (2003) Modulation of estrogen receptor activity by selective coregulators. J Steroid Biochem Mol Biol 85:117-22
Nye, Anne C; Rajendran, Ramji R; Stenoien, David L et al. (2002) Alteration of large-scale chromatin structure by estrogen receptor. Mol Cell Biol 22:3437-49
Martini, P G; Katzenellenbogen, B S (2001) Regulation of prothymosin alpha gene expression by estrogen in estrogen receptor-containing breast cancer cells via upstream half-palindromic estrogen response element motifs. Endocrinology 142:3493-501
Wang, C; Fu, M; Angeletti, R H et al. (2001) Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276:18375-83
Lazennec, G; Thomas, J A; Katzenellenbogen, B S (2001) Involvement of cyclic AMP response element binding protein (CREB) and estrogen receptor phosphorylation in the synergistic activation of the estrogen receptor by estradiol and protein kinase activators. J Steroid Biochem Mol Biol 77:193-203
Choi, I; Ko, C; Park-Sarge, O K et al. (2001) Human estrogen receptor beta-specific monoclonal antibodies: characterization and use in studies of estrogen receptor beta protein expression in reproductive tissues. Mol Cell Endocrinol 181:139-50
Delage-Mourroux, R; Martini, P G; Choi, I et al. (2000) Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J Biol Chem 275:35848-56
Katzenellenbogen, B S; Montano, M M; Ediger, T R et al. (2000) Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 55:163-93; discussion 194-5
Katzenellenbogen, B S; Choi, I; Delage-Mourroux, R et al. (2000) Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 74:279-85
de Haan, G; Chusacultanachai, S; Mao, C et al. (2000) Estrogen receptor-KRAB chimeras are potent ligand-dependent repressors of estrogen-regulated gene expression. J Biol Chem 275:13493-501

Showing the most recent 10 out of 26 publications